X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals launched a public offering of 45,860,000 shares of common stock and, in lieu of shares for certain investors, pre-funded warrants to purchase 700,000 shares. The public offering price is $2.90 per share and $2.899 per pre-funded warrant, for gross proceeds of $135,023,300. After underwriting discounts and estimated expenses, expected net proceeds are about $126.6 million. Underwriters have a 30‑day option to buy up to 6,984,000 additional shares.
X4 intends to use proceeds to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders and for general corporate purposes. Pre‑funded warrants carry a $0.001 exercise price, are immediately exercisable, do not expire, and are subject to ownership limits; they will not be listed. Common stock trades on Nasdaq as XFOR. Shares outstanding would be 53,819,947 after the offering, assuming no warrant exercises and no option exercise. The company estimates immediate dilution of $1.02 per share to new investors.
X4 Pharmaceuticals filed a preliminary prospectus supplement for a primary offering of common stock and, for certain investors, pre-funded warrants. The pre-funded warrants are priced at the share offering price minus $0.001 (their exercise price), are exercisable immediately, do not expire, and include an ownership cap of 9.99% (or 4.99% at the holder’s election). The underwriters have a 30-day option to purchase additional shares at the public offering price, less the underwriting discount.
X4 expects to use net proceeds, together with existing cash and cash flows from operations, to fund the pivotal Phase 3 development of mavorixafor in chronic neutropenic disorders and for general corporate purposes, including G&A, capital expenditures, and working capital. Certain officers have indicated interest in purchasing shares at the public offering price. X4’s common stock trades on Nasdaq as “XFOR”; the last reported sale price was $3.10 on October 22, 2025. Shares outstanding were 7,959,947 as of June 30, 2025.
Coastlands Capital and affiliated entities filed a Schedule 13G reporting beneficial ownership of 2,491,638 shares of X4 Pharmaceuticals (XFOR) common stock, representing 9.99% of the class. The filing shows shared voting and dispositive power over these shares and no sole power.
The calculation is based on 22,449,689 shares outstanding as of August 13, 2025, as cited from an issuer filing, and includes shares issuable upon exercise of pre-funded warrants, reflecting a 9.99% beneficial ownership limitation. The reporting persons state the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
X4 Pharmaceuticals is undertaking a major restructuring to focus resources on completing its 4WARD Phase 3 trial in chronic neutropenia. The plan includes reducing its workforce by approximately 50%, which is expected to generate about $13 million in annualized cost savings and result in an estimated $3.3 million of severance and related cash charges.
As part of the actions, the company terminated its Chief Operating Officer, Chief Commercial Officer, and Chief Legal & Compliance Officer effective September 15, 2025, and its Chief Medical Officer resigned effective September 16, 2025. The Board appointed John Volpone as Chief Operating Officer, and he will also continue serving as President. X4 notes that actual restructuring costs and benefits may differ from current estimates.
X4 Pharmaceuticals, Inc. filed a shelf registration on Form S-3 to register resale of shares held by selling stockholders and to cover various resale methods. The company notes its common stock trades on Nasdaq under XFOR and reported a last sale price of $3.39 on September 8, 2025. X4 highlights the April 29, 2024 FDA approval of mavorixafor marketed as XOLREMDI for patients 12+ with WHIM syndrome and sale of its pediatric review voucher. The filing discloses a 1-for-30 reverse stock split effective April 28, 2025 and contains PwCs audit report with an explanatory paragraph regarding the companys ability to continue as a going concern. The prospectus describes extensive pre-funded warrants and beneficial ownership limitations held by institutional investors and standard indemnification and resale mechanics for Selling Stockholders.
X4 Pharmaceuticals, Inc. has filed a new Form S-8 registration statement to increase the number of shares available under its Amended and Restated 2019 Inducement Equity Incentive Plan. This filing uses a streamlined process that incorporates by reference several prior S-8 registration statements covering the same plan and other employee benefit plans.
The company lists its key governing documents, the equity plan itself, and related legal opinions and consents as exhibits. The registration statement is signed on behalf of X4 Pharmaceuticals by Executive Chairman Adam R. Craig and other senior officers and directors, who also grant powers of attorney to authorize future amendments to this S-8.
X4 Pharmaceuticals, Inc. filed a Form D reporting a Regulation D, Rule 506(b) exempt offering that raised $84,999,985, with the entire amount marked as sold and $0 remaining. The filing indicates the first sale date as 2025-08-13 and the issuer lists its principal place of business in Boston, Massachusetts. The offering included equity and options/warrants (and the securities to be acquired upon exercise) and reports 18 investors to date. Sales commissions are disclosed as $3,300,000 (estimated). The Form D was signed by Chief Legal Officer Natasha Thoren on behalf of the issuer.
X4 Pharmaceuticals, Inc. reported that on August 22, 2025, directors David McGirr and R. Keith Woods resigned from its board of directors, including all board committees, effective immediately. The company stated that their resignations were not due to any disagreement regarding operations, policies, or practices.
Following these departures, Michael Wyzga was appointed chair of the board’s audit committee, and Francoise de Craecker and Gary Bridger were appointed as members of the audit committee, ensuring the committee remains staffed to oversee the company’s financial reporting and controls.
Biotechnology Value Fund and affiliated entities disclosed beneficial ownership stakes in X4 Pharmaceuticals (XFOR). Collectively certain Reporting Persons hold 2,243,659 shares, representing approximately 9.9% of the outstanding common stock on the filing date. Individually, BVF holds 1,168,649 shares (~5.2%), BVF2 holds 906,855 shares (~4.0%), and Biotechnology Value Trading Fund OS holds 123,369 shares (less than 1%). The reporting group also holds pre-funded warrants exercisable for an aggregate of 1,288,288 shares at $0.001 per share, subject to a blocker that limits current exercisable warrants to 9,917 shares for the Reporting Persons as of August 20, 2025. The filing clarifies shared voting and dispositive powers among fund entities, GP entities, Partners, BVF Inc. and Mark N. Lampert and includes a joint filing agreement as Exhibit 99.1.
Deep Track entities and David Kroin report beneficial ownership of 2,366,995 shares of X4 Pharmaceuticals (XFOR), representing 9.99% of the class. The filing shows shared voting and dispositive power over those shares and states the position was not acquired to change control. The beneficial-ownership calculation references the issuer's reported share counts and convertible instruments and notes the inclusion of 4,162,137 pre-funded warrants exercisable subject to a 9.99% maximum-percentage exercise limitation that prevents exercise if it would push ownership above 9.99%. The filing is a joint Schedule 13G by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin and includes signatures dated August 19, 2025.